Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study
1. GTx-104 trial met primary endpoint, showing clinical benefit over nimodipine. 2. GTx-104 reduced hypotension incidents by 19% in hospitalized aSAH patients. 3. 54% dose intensity for GTx-104 patients was significantly higher than for nimodipine. 4. Grace Therapeutics plans $30 million private placement to fund GTx-104 development. 5. Current GRCE stock price is $3.38, reflecting positive investor sentiment.